ArticleScientific reports2025
Perceptions of targeted sexual healthcare among French MSM based on HPV vaccination policy in France.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessment of knowledge, attitudes, and behaviors regarding vaccinations among LGBTQIA+ community in Italy.Human vaccines & immunotherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Human papillomavirus (HPV) vaccination in France is recommended for persons of both sexes up to 19 years of age. This increases to 26 years for men who have sex with men (MSM), as they are considered a high-risk group. Raising the upper age limit for MSM is a targeted sexual healthcare policy because it takes into account the specificities of MSM sexual practices. Assessing MSM's perceptions of targeted sexual healthcare, using HPV vaccination as an example, is crucial for improving public health policy and HPV recommendations. As part of the French mixed-methods study Vaccigay, we conducted a qualitative study-using semi-structured interviews-with MSM selected by age and HPV vaccination status in 2022. Interviews were transcribed verbatim and thematically analysed using NVivo. Some respondents supported targeted sexual healthcare policy for MSM because they recognised the epidemiological factors involved and wanted healthcare workers to have a non-judgmental attitude toward them. Others did not because they felt it stigmatised MSM; they advocated equal sexual healthcare for everyone. Ultimately, uncertainty about one's own sexual orientation and difficulty discussing sexuality with doctors were barriers to accessing targeted sexual health care. We recommend improving training of healthcare workers on the specific needs of sexual and gender minorities, increasing the number of sexual health centres that serve these populations, and extending HPV vaccination to all adults up to the age of 26, irrespective of sexual orientation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.